Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10907309 | Experimental Hematology | 2015 | 10 Pages |
Abstract
Our aim was to study the influence of acute graft-versus-host disease (a-GVHD) on primary engraftment times after allogeneic transplantation. Primary engraftment and frequency of marrow granulocyte-macrophage colony-forming units and erythroid burst-forming units, at day +18, were studied in 126 allogeneic transplants. Patients were grouped according to the time when a-GVHD treatment with corticosteroids was started. The no-a-GVHD group are those who, during the first 3 months, had no need for a-GVHD treatment; the early-a-GVHD group are those who needed a-GVHD treatment within 19 days; and the postengraftment-a-GVHD group are those who were not on corticosteroid treatment at the time of engraftment but needed it after day +19. The no-a-GVHD group reached a neutrophil count (N) > 0.5 Ã 109/L in a median of 17.8 days. The postengraftment-a-GVHD group reached N > 0.5 Ã 109/L in a median of 21.4 days (p = 0.0003). The early-a-GVHD group had N > 0.5 Ã 109/L in a median of +17.0 days (p = 0.23). When factors important for engraftment were studied in a multivariate analysis, postengraftment a-GVHD was a significant factor in delayed neutrophil and platelet engraftment. Both the early-a-GVHD and postengraftment-a-GVHD groups showed a significant reduction in frequency of granulocyte-macrophage colony-forming units and erythroid burst-forming units found in marrow at day +18. In conclusion, a-GVHD may influence early marrow reconstitution and is a relevant factor for primary myeloid and platelet engraftment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Giuseppe Milone, Maria Grazia Camuglia, Giuseppe Avola, Annalia Di Marco, Salvatore Leotta, Alessandra Cupri, Paolo Spina, Alessandra Romano, Eleonora Spina, Maria Pia Azzaro, Deja Berritta, Marina Parisi, Giovanni Tripepi,